An old, generic malaria drug has rapidly become a leading potential coronavirus treatment, as President Donald Trump has repeatedly touted its potential against the virus and the US government has built up a massive stockpile of the medication.
Sarah Lofgren’s voice had a tinge of excitement when she explained why the bright green dots on one scientific slide disappeared on the next. The co-investigator at the University of Minnesota Division of Infectious Disease and International Medicine showed how SARS, or severe acute respiratory syndrome, represented by those green dots, responded to all the drugs that were thrown at it to determine what could hinder the virus.
Pharmaceutical companies Novartis and Rising Pharmaceuticals are taking action to support the latest clinical trials exploring hydroxychloroquine as a treatment for the coronavirus disease 2019 (COVID-19).
For a clinical trial exploring hydroxychloroquine as preventive treatment for COVID-19
Rising Pharmaceuticals Bolsters U.S. Supply Chain by Expanding Sterile Dosage Capabilities, Including Injectables and Ophthalmics, with Opening of New Facility
Rising Pharmaceuticals Bolsters U.S. Supply Chain by Expanding Sterile Dosage Capabilities, Including Injectables and Ophthalmics, with Opening of New Facility
From our manufacturers, partners and pharmacies to physicians and their patients, our goal is to make life better for everyone we impact.